GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DRI Healthcare Trust (OTCPK:DHTRF) » Definitions » Beta

DHTRF (DRI Healthcare Trust) Beta : N/A (As of Dec. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is DRI Healthcare Trust Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-14), DRI Healthcare Trust's Beta is Not available.


DRI Healthcare Trust Beta Historical Data

The historical data trend for DRI Healthcare Trust's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DRI Healthcare Trust Beta Chart

DRI Healthcare Trust Annual Data
Trend Dec21 Dec22 Dec23
Beta
- - -

DRI Healthcare Trust Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DRI Healthcare Trust's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DRI Healthcare Trust's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's Beta distribution charts can be found below:

* The bar in red indicates where DRI Healthcare Trust's Beta falls into.



DRI Healthcare Trust Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


DRI Healthcare Trust  (OTCPK:DHTRF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


DRI Healthcare Trust Beta Related Terms

Thank you for viewing the detailed overview of DRI Healthcare Trust's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


DRI Healthcare Trust Business Description

Comparable Companies
Traded in Other Exchanges
Address
100 King Street West, 1 First Canadian Place, Suite 7250, Toronto, ON, CAN, M5X 1B1
DRI Healthcare Trust is engaged in pharmaceutical royalty monetization by providing capital to inventors, academic institutions, and biopharma companies. Trust was formed to provide Unitholders with differential exposure to the pharmaceutical and biotechnology industries through ownership and acquisitions of pharmaceutical royalties. In return for providing capital to biopharmaceutical innovators, the company is building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. The Trust has concluded that it operates as one segment, primarily focused on acquiring royalty assets. Geographically the trust generates major revenue from the United States. The trust also generates Income from markets such as Japan, and the European Union.